168 related articles for article (PubMed ID: 38243282)
1. Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.
Guo L; Cheng H; Liu J; Shao W; Luo L; Zheng W; Sun S; Kong D; Chen C
BMC Med Genomics; 2024 Jan; 17(1):25. PubMed ID: 38243282
[TBL] [Abstract][Full Text] [Related]
2. MiR-98-5p/IGF2 Axis Influence Herceptin Sensitivity through IGF1R/HER2 Heterodimer Formation and AKT/mTOR Signal Pathway in HER2 Positive Breast Cancer.
Zhang M; Li Z; Liu X
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3693-3703. PubMed ID: 34837929
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract][Full Text] [Related]
4. Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer.
Buiga P; Elson A; Tabernero L; Schwartz JM
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357550
[TBL] [Abstract][Full Text] [Related]
5. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808
[TBL] [Abstract][Full Text] [Related]
6. Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis.
Buiga P; Elson A; Tabernero L; Schwartz JM
BMC Syst Biol; 2018 Apr; 12(Suppl 1):11. PubMed ID: 29671404
[TBL] [Abstract][Full Text] [Related]
7. Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.
Ahmad S; Gupta S; Kumar R; Varshney GC; Raghava GP
Sci Rep; 2014 Mar; 4():4483. PubMed ID: 24670875
[TBL] [Abstract][Full Text] [Related]
8. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
9. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
10. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
Gu L; Waliany S; Kane SE
PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
[TBL] [Abstract][Full Text] [Related]
11. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
[TBL] [Abstract][Full Text] [Related]
12. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z
Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189
[TBL] [Abstract][Full Text] [Related]
15. Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.
Li C; Liu H; Zhang B; Gong L; Su Y; Zhang Z; Wang C
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1079-1086. PubMed ID: 29616327
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
17. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
[TBL] [Abstract][Full Text] [Related]
19. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
20. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
Ríos-Luci C; Díaz-Rodríguez E; Gandullo-Sánchez L; Díaz-Gil L; Ocaña A; Pandiella A
Cancer Lett; 2020 Feb; 470():161-169. PubMed ID: 31765734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
